Product
Help
Pricing
About
Jobs
Log in
Get started
Institution
Add to collection
Harmony Biosciences (United States)
Homepage:
harmonybiosciences.com
Alternate names:
Harmony Biosciences,
Harmony Biosciences Holdings, Inc.
ROR:
03kz8nj22
OpenAlex ID:
I4405272122
Evaluation of the abuse potential of pitolisant, a selective H3-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy
2019
·
Beatrice Setnik
, Michael McDonnell
, et al.
·
SLEEP
·
190
PDF
Evaluation of a virtual reality enhanced bullying prevention curriculum pilot trial
2019
·
Katherine M. Ingram
, Dorothy L. Espelage
, et al.
·
Journal of Adolescence
·
127
Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials
2021
·
Gerard J. Meskill
, Craig W. Davis
, et al.
·
CNS Drugs
·
16
PDF
Efficacy of pitolisant in patients with high burden of narcolepsy symptoms: pooled analysis of short-term, placebo-controlled studies
2021
·
Craig W. Davis
, Ulf Kallweit
, et al.
·
Sleep Medicine
·
15
PDF
Clinician- and Patient-reported Endpoints in CNS Orphan Drug Clinical Trials: ISCTM Position Paper on Best Practices for Endpoint Selection, Validation, Training, and Standardization.
2021
·
Joan Busner
, Gahan Pandina
, et al.
·
PubMed
·
11
Establishing the content validity of the Epworth Sleepiness Scale for Children and Adolescents in Prader-Willi syndrome
2021
·
Vanessa Perez Patel
, Albena Patroneva
, et al.
·
Journal of Clinical Sleep Medicine
·
10
PDF
Time to Onset of Response to Pitolisant for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients With Narcolepsy: An Analysis of Randomized, Placebo-Controlled Trials
2021
·
Nathaniel F. Watson
, Craig W. Davis
, et al.
·
CNS Drugs
·
6
PDF
Ensuring Stakeholder Feedback in the Design and Conduct of Clinical Trials for Rare Diseases: ISCTM Position Paper of the Orphan Disease Working Group.
2024
·
Gahan J Pandina
, Joan Busner
, et al.
·
PubMed Central
·
5
PDF
A proof-of-concept study of pitolisant for excessive daytime sleepiness in patients with Prader-Willi syndrome
2025
·
Amee Revana
, Rakesh Bhattacharjee
, et al.
·
Journal of Clinical Sleep Medicine
·
4
PDF
0614 Safety and Tolerability of Pitolisant in the Treatment of Adults With Narcolepsy: Integrated Data From Clinical Studies
2019
·
Catherine Scart-Grès
, Chinedu Momah
, et al.
·
SLEEP
·
4
A Blue-Enriched Light Intervention Counteracts the Alertness Decrement Among Mine Workers on Extended 12-Hour Night Shift Periods
2023
·
Marc Hébert
, Andrée-Anne Lavigne
, et al.
·
Journal of Occupational and Environmental Medicine
·
3
0744 Cardiac Safety Profile of Pitolisant in Patients with Narcolepsy
2020
·
W Winter
, S P Wanaski
, et al.
·
SLEEP
·
3
0615 Pitolisant in Combination With Other Medications for the Management of Narcolepsy
2019
·
Karl Doghramji
, Craig W Davis
, et al.
·
SLEEP
·
3
0867 Effect of Pitolisant on Symptoms of Idiopathic Hypersomnia During an Open-Label Period in a Phase 3 Clinical Trial
2025
·
Bruce Corser
, David Plante
, et al.
·
SLEEP
·
2
PDF
0895 Pharmacokinetics of pitolisant in breast milk and serum of healthy lactating women
2023
·
Virginia Schmith
, Neha Bhise
, et al.
·
SLEEP
·
2
PDF
Pitolisant for the treatment of cataplexy in adults with narcolepsy
2021
·
Gerard J. Meskill
, Ulf Kallweit
, et al.
·
Expert Opinion on Orphan Drugs
·
2
Efficacy and safety of pitolisant in patients with narcolepsy: a review of clinical trials
2019
·
Y. Dauvilliers
, J.-C. Schwartz
, et al.
·
Sleep Medicine
·
2
0611 The Safety and Tolerability of Pitolisant in the Treatment of Excessive Daytime Sleepiness and Cataplexy in Adult Patients With Narcolepsy: An Open-Label, Expanded Access Program in the United States
2019
·
Eric D Bauer
, Craig W Davis
, et al.
·
SLEEP
·
2
Long-term safety and tolerability of transdermal cannabidiol gel in children and adolescents with Fragile X syndrome (ZYN2-CL-017): an interim analysis of an ongoing open-label extension study
2025
·
Elizabeth Berry-Kravis
, Randi Hagerman
, et al.
·
Journal of Neurodevelopmental Disorders
·
1
PDF
A 20-Week Multicenter, Randomized, Double-Blind (DB), Placebo-Controlled, Phase 3 Trial (EPX 100-003) of EPX-100 (Clemizole Hydrochloride) as Adjunctive Therapy in patients with Lennox-Gastaut Syndrome (LGS) (P8-9.007)
2025
·
Amit Ray
, George Nomikos
, et al.
·
Neurology
·
1
0909 Pitolisant Pregnancy Registry: An Observational Study of the Safety of Pitolisant Exposure in Pregnant Women and Their Offspring
2023
·
Anthony Adamkovic
, Padge Montgomery
, et al.
·
SLEEP
·
1
PDF
PRO60 The Epworth Sleepiness Scale for Children and Adolescents Is a Fit-for-Purpose Measure of Daytime Sleepiness in Prader-Willi Syndrome: A Qualitative Interview Study
2021
·
V. Patel
, K. Davis
, et al.
·
Value in Health
·
1
Cardiac Safety Profile of Pitolisant in Patients With Narcolepsy (1472)
2021
·
William Winter
, Stephen Wanaski
, et al.
·
Neurology
·
1
Pitolisant in combination with other medications for the management of narcolepsy
2019
·
K. Doghramji
, C. Davis
, et al.
·
Sleep Medicine
·
1
Safety and tolerability of pitolisant in the treatment of adults with narcolepsy: integrated data from clinical studies
2019
·
C. Scart-Grès
, C. Momah
, et al.
·
Sleep Medicine
·
1
Show more works
View as search
Works count:
66
Citation count:
693
Year
Topic
Type
